Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions
OsteoporosisSystemic Mastocytosis
Interventions
DRUG

Denosumab

Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections

DRUG

Placebo

Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections

Trial Locations (11)

13385

La Timone Hospital, Dermatology and cutaneous oncology department, Marseille

14033

Caen Hospital, Clinical haematology department, Caen

25030

Jean Minjoz Hospital, Dermatology department, Besançon

31060

Toulouse Hospital, Dermatology department, Toulouse

34295

Lapeyronie Hospital, Rheumatology and Immunology department, Montpellier

59037

Lille CHRU Hospital, Internal medicine and clinical immunology department, Lille

63100

Estaing Hospital, Cellular therapy and clinical haematology department, Clermont-Ferrand

67098

Strasbourg Hospital, Rheumatology department, Strasbourg

75013

La Pitié-Salpêtrière Hospital, Internal medicine and clinical immunology department, Paris

75014

Cochin Hospital, Rheumatology department, Paris

75015

Necker Hospital, Adult haematology department, Paris

All Listed Sponsors
collaborator

CEREMAST

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03401060 - Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis | Biotech Hunter | Biotech Hunter